
Sign up to save your podcasts
Or
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
4.7
1919 ratings
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
291 Listeners
314 Listeners
48 Listeners
861 Listeners
492 Listeners
14 Listeners
90 Listeners
25 Listeners
513 Listeners
132 Listeners
349 Listeners
183 Listeners
365 Listeners
5 Listeners
79 Listeners